CF Foun­da­tion, Long­wood team on new in­cu­ba­tor for com­pa­nies with cut­ting-edge CF treat­ments

Nine months af­ter launch­ing a $500 mil­lion hunt for a cure for cys­tic fi­bro­sis, the Cys­tic Fi­bro­sis Foun­da­tion said it will use a por­tion of those funds to do some­thing it has nev­er done be­fore: help launch new com­pa­nies.

The CF Foun­da­tion, whose ven­ture phil­an­thropy ef­forts helped fund Ver­tex’s line of pow­er­ful CF drugs, is team­ing with Long­wood Fund to cre­ate a CF in­cu­ba­tor. The in­cu­ba­tor will iden­ti­fy new com­pa­nies with plat­forms or tech­nolo­gies that can be ap­plied in the rare ge­net­ic con­di­tion. The part­ners can then fi­nance ear­ly de­vel­op­ment in ex­change for a com­mit­ment from the com­pa­nies to fo­cus on ap­pli­ca­tions in cys­tic fi­bro­sis.

CF Foun­da­tion has com­mit­ted up to $20 mil­lion to the ef­fort, al­though the com­pa­nies se­lect­ed could al­so re­ceive fund­ing through Long­wood’s tra­di­tion­al ear­ly-stage VC ef­forts.

David Stein­berg

“This is new, so we’ll have to see how it plays out in prac­tice,” Long­wood part­ner David Stein­berg told End­points News. 

The idea for the in­cu­ba­tor emerged last Oc­to­ber at Har­vard Med­ical School, where Long­wood was hold­ing their bian­nu­al meet­ing with non-prof­its and pa­tient groups. At the time, the CF Foun­da­tion was prepar­ing to launch its $500 mil­lion Path to a Cure ini­tia­tive. Trikaf­ta, the third of Ver­tex’s three small-mol­e­cule CF drugs, was about to hit mar­ket, but al­though the new drug meant 90% of CF pa­tients could now be treat­ed, that still left 10% un­treat­ed. Armed with roy­al­ties from Ver­tex, the Path ini­tia­tive would try to back tech­nolo­gies that could treat that last group of pa­tients and ul­ti­mate­ly, per­haps, lead to a cure.

The CF Foun­da­tion had long backed aca­d­e­m­ic work and par­tic­u­lar pro­grams at es­tab­lished com­pa­nies — Ver­tex kept up their ear­ly CF work in part be­cause the foun­da­tion was fund­ing it — but it had nev­er tried to found new ones. But such an ear­ly-stage ap­proach made par­tic­u­lar sense for what the foun­da­tion was now try­ing to ac­com­plish, foun­da­tion CEO Mike Boyle told End­points.

Mike Boyle

Cys­tic fi­bro­sis in­volves a mal­func­tion­ing trans­port pro­tein in the lungs, called CFTR. Ver­tex’s drugs ei­ther help that pro­tein fold in the right way or guide it to the right place. The re­main­ing 10% of pa­tients, though, ei­ther have a pro­tein mis­fold­ed in such a way it doesn’t re­spond to ex­ist­ing small mol­e­cules or they sim­ply don’t have the pro­tein at all.

That meant pa­tients would have to be treat­ed with tech­nolo­gies that can tar­get the gene: gene ther­a­py, gene edit­ing, and RNA drugs, among oth­ers. Boyle said the foun­da­tion is in ear­ly talks with 17 biotechs, most­ly small, with such plat­forms. Many larg­er com­pa­nies with these plat­forms are fo­cused in oth­er ar­eas.

“One of the chal­lenges right now is that there are eas­i­er tar­gets for gene ther­a­py than CF,” Boyle said.

It’s dif­fi­cult to get gene ther­a­py in­to the lungs, where the im­mune re­sponse is unique and cells turn over at a high­er rate than in oth­er parts of the body. But the in­cu­ba­tor could al­low Long­wood and the foun­da­tion to steer com­pa­nies that are just start­ing out to this chal­lenge in ex­change for the fund­ing they need to get off the ground. Those star­tups would al­so have ac­cess to the foun­da­tion’s sci­en­tif­ic ad­vi­sors, their CF lab in Boston and their CF clin­i­cal tri­al net­work.

In ad­di­tion to spe­cif­ic ther­a­pies, the in­cu­ba­tor may al­so in­vest in drug de­liv­ery tech­nol­o­gy, such as ex­o­somes, that could make de­liv­er­ing DNA, RNA or oth­er types of drugs to the lungs.

There is prece­dent for the ap­proach. The Gates Foun­da­tion’s ven­ture arm has long in­vest­ed in ear­ly-stage im­munol­o­gy plat­forms in ex­change for a com­mit­ment from the com­pa­nies to fo­cus part of their work on in­fec­tious dis­ease and not just can­cer or au­toim­mune dis­or­ders.

Boyle said they’re hop­ing to launch com­pa­nies with­in a cou­ple years, but they’re al­so con­tin­u­ing to so­lic­it part­ner­ships with aca­d­e­m­ic cen­ters and more es­tab­lished biotechs. The in­cu­ba­tor’s $20 mil­lion is just a small por­tion of Path’s $500 mil­lion vault.

“This is the be­gin­ning of the process,” Boyle said. “We are open for busi­ness.”

So­cial im­age: Mike Boyle, Cys­tic Fi­bro­sis Foun­da­tion via YouTube

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA have vowed not to let politics get in the way of science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped health agencies under his purview — including the FDA — of their rulemaking ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Eli Lilly CSO Dan Skovronsky (file photo)

#ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mutant non-small cell lung cancer has turned up some promising — although decidedly early — results, fueling the idea that there’s yet room to one up on third-generation tyrosine kinase inhibitors.

Twenty out of 20 advanced NSCLC patients had a response after taking a combination of an in-house TKI dubbed lazertinib and amivantamab, a bispecific antibody targeting both EGFR and cMET engineered on partner Genmab’s platform, J&J reported at ESMO. All were treatment-naïve, and none has seen their cancer progress at a median follow-up of seven months.

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

AstraZeneca has unveiled the final, mature overall survival data that cemented Lynparza’s first approval in prostate cancer approval — touting its lead against rivals with the only PARP inhibitor to have demonstrated such benefit.

But getting the Merck-partnered drug to the right patients remains a challenge, something the companies are hoping to change with the new data cut.

The OS numbers on the subgroup with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer are similar to the first look on offer when the FDA expanded the label in May: Lynparza reduced the risk of death by 31% versus Xtandi and Zytiga. Patients on Lynparza lived a median of 19.1 months, compared to 14.7 months for the anti-androgen therapies (p = 0.0175).

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

Dan Skovronsky, Eli Lilly CSO

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.

Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.

There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.